Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

N-3 polyunsaturated fatty acids restore Th17 and Treg balance in collagen antibody-induced arthritis

  • Ji Young Kim,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

    Affiliation Division of Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Republic of Korea

  • Kyu Lim,

    Roles Conceptualization, Project administration, Writing – review & editing

    Affiliation Department of Biochemistry and Cancer Research Institute, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

  • Kyung Hee Kim,

    Roles Formal analysis

    Affiliation Department of Pathology, Cancer Research Institute, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

  • Jin Hyun Kim,

    Roles Methodology

    Affiliation Division of Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Republic of Korea

  • Jin Sun Choi,

    Roles Data curation, Formal analysis

    Affiliation Division of Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Republic of Korea

  • Seung-Cheol Shim

    Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing

    shimsc@cnuh.co.kr

    Affiliation Division of Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Republic of Korea

N-3 polyunsaturated fatty acids restore Th17 and Treg balance in collagen antibody-induced arthritis

  • Ji Young Kim, 
  • Kyu Lim, 
  • Kyung Hee Kim, 
  • Jin Hyun Kim, 
  • Jin Sun Choi, 
  • Seung-Cheol Shim
PLOS
x

Abstract

N-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory effects and were considered useful for the treatment of rheumatoid arthritis (RA). Recently, several studies suggested that n-3 PUFAs attenuated arthritis in animal model and human, however the mechanism is still unclear. Interleukin 17 (IL-17) is a pro-inflammatory cytokine mainly produced by T helper 17 (Th17) cells which cause tissue inflammation and bone erosion leading to joint destruction. In contrast, regulatory T (Treg) cells down-regulate various immune responses by suppression of naïve T cells. The imbalance between Th17 cells and Tregs cell is important for the pathogenesis of RA. Here, we investigated whether n-3 PUFAs attenuate arthritis in collagen antibody-induced arthritis (CAIA) model. We used fat-1 transgenic mice expressing the Caenorhabditis elegans fat-1 gene encoding an n-3 fatty acid desaturase that converts n-6 to n-3 fatty acids, leading to abundant n-3 fatty acids without the need of a dietary n-3 supply. Clinical arthritis score was significantly attenuated in fat-1 mice compared to wild type (WT) mice on day 7 (1.6±1.8, p = 0.012) and day 9 (1.5±1.6, p = 0.003). Ankle thickness also decreased significantly in fat-1 mice compared to WT mice (1.82±0.11, p = 0.008). The pathologic finding showed that inflammatory cell infiltration and bone destruction were reduced in fat-1 mice compared to WT. The expression levels of IL-17 and related cytokines including IL-6 and IL-23 decreased in the spleen and ankle joint tissue of fat-1 mice compared to WT mice. Furthermore, Treg cells were expanded in the spleen of fat-1 mice and Treg cell differentiation was significantly higher in fat-1 mice than in wild type (p = 0.038). These data suggest that n-3 PUFAs could attenuate arthritis through increasing the expression of FoxP3 and the differentiation of Treg, while reducing IL-17 production. Therefore, dietary supplementation of n-3 PUFAs could have a therapeutic potential for the treatment of RA.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of a joint synovium, leading to progressive bone and cartilage destruction [1]. Recently, T helper 17 (Th17) cells have been suggested to play key roles in RA induction and maintenance. Th17 cells are pro-inflammatory cells, which produce interleukin 17 (IL-17) and differentiation is dependent on IL-6, IL-23 and TGF-β [2,3]. IL-17 is raised in synovial fluids of RA patients and in inflamed joints of experimental induced arthritis models. IL-17 induces inflammatory cell infiltration into the synovium and tissue inflammation, leading into bone resorption and erosion [4]. In contrast CD4+CD25+Foxp3+ regulatory T cell (Treg) regulates the immune response to keep peripheral self-tolerance [5]. Th17 and Treg cells antagonize each other’s function, the imbalance between Th17 and Treg cells may be important in the development of RA.

N-3 polyunsaturated fatty acid (n-3 PUFA) has shown anti-inflammatory effect through immune cell inhibition [68]. N-3 PUFAs are primarily obtained from the diet, only low conversion of α-linolenic acid (ALA) to eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) [9]. Recently, experimental animal studies reported that n-3 PUFAs suppress inflammatory cytokine synthesis [10]. In addition, n-3 PUFAs reduced the number and differentiation of pro-inflammatory Th17 cells [78, 11] and increased number of Treg cells in vivo [12]. A fat-1 transgenic mouse expresses the Caenorhabditis elegans fat-1 gene encoding an n-3 fatty acid desaturase that converts n-6 to n-3 fatty acids (which is absent in mammals), leading to abundant n-3 fatty acids with reduced levels of n-6 fatty acids in their organs and tissues, without the need of a dietary n-3 supply [13]. Furthermore, fat-1 mice delayed the development of osteoarthritis [14] and decreased the severity of arthritis in K/BxN serum transfer arthritis model [15]. Compared with n-3 PUFAs feeding studies, studies using fat-1 mice could withdraw confounding factors of diet such as nutrient composition, total caloric intake, duration of feeding and contamination of trace elements. The fat-1 mice have got resistibility in various inflammatory disease models such as pancreatitis [16] and asthma [17].

We used the collagen antibody-induced arthritis (CAIA) model which is induced by the administration of cocktail of monoclonal antibodies recognizing conserved epitopes located within the CB11 fragment of collagen. CAIA offers several advantages, including rapid disease onset, high uptake rate, and the capacity to use genetically modified mice, such as transgenics and knockouts [18].

The purpose of our study was to investigate whether n-3 PUFAs in fat-1 mice attenuated CAIA.

Materials and methods

Animals

Ethics Statement.

All animal experiments were performed under the Institutional Animal Care and Use Committee of Chungnam National University Hospital (IACUC, Approval No. CNUH-015-A0010) which arrpoved the current study protocol and the ARRIVE Guidelines (Animals in Research: Reporting In Vivo Experiments). All efforts were made for minimize animal suffering. The animals were kept in groups (5 animals per cage) under controlled conditions with 12 hour light/dark cycle and monitored once daily for nine days following the first immunization. In this study, anaerobes were not necessary because they did not perform surgical surgery to induce arthritis. Also, this was not necessary for pain relievers because it was not a drug treatment experiment, and arthritis were milder and duration of experiments was short. At the end of the survival experiment, live animals were euthanized by zoletil(90mg/kg)/rompun(30mg/kg) overdose. Total 11 animals were used for this study, all the mice were euthanized.

Fat-1 transgenic mice.

Fat-1 transgenic mice were kindly provided from Dr.J.X. Kang at the Harvard Medical School (Boston, MA, USA) [19]. The mice were kept under specific pathogen free conditions in standard cage, and 7–8 weeks old males were used for the experiment.

Collagen antibody-induced arthritis mice.

To induce arthritis, the AthritoMabTMCllmAb cocktail (4 mg/mouse, MD bioscience GmbH, Zurich, Switzerland) was injected intravenously. Three days after antibody administration, 100 μg LPS (Escherichria coli 055:B5; MD Biosciences) was injected intra-peritoneally. The experiment was ended 9 days after antibody administration.

Arthritis evaluation

The severity of arthritis was assessed by clinical arthritis score and hind paw thickness. Clinical arthritis scores were evaluated using a scale of 0–4 for each limb (0 = no swelling; 1 = slight swelling and erythema; 2 = moderate swelling and erythema; 3 = severe swelling and erythema; and 4 = maximal inflammation with joint rigidity). The maximum possible score for each mouse was 16. Ankle thickness was measured using a caliper placed across the ankle joint at the widest point. On day 9, the mice were sacrificed and joint tissues were harvested from each animal for end point histology.

Determination of cytokine concentrations

IL-6, IL-17 and IL-23 levels in whole blood were determined using Milliplex® MAP kit (KomaBiotech, Korea) according to the manufacturer’s instruction.

BioRad (Hercules, CA) Bio-Plex kits were used for cytokine assays from joint lysates. All samples were run in duplicate and were assayed for murine IL-6, IL-17 and IL-23 multi-plex bead based kits. The assays were run according to manufactures recommended procedures. In brief, all buffers and diluents were warmed to room temperature prior to use. Lyophilized cytokine standards were reconstituted first to a mater standard stock using 250ul diluted according to manufacturer’s direction. Four-fold serial dilutions of the master standard stock provided eight concentrations used to determine a standard curve. The concentration ranges of the standards were: IL-6: 7.8–8000 pg/ml; IL-17: 39–40000 pg/ml; IL-23: 342–350000 pg/ml. After completion of all steps in the assay, the plates were read in Luminex 200 system and the data analyzed using BioPlex Manager 6 software.

Immunoblotting

Protein was isolated from joint tissue using RIPA buffer. After sonication, the joint lysate was collected by centrifugation at the speed of 13000g at 4°C for 10 min to remove lysate debris and stored in aliquots at -80°C until used. The protein concentration in the cell extracts were determined by the Bio-Rad protein assay (Bio-Rad, CA). Fifty micrograms of tissue protein were subjected to SDS-PAGE on 4% to 20% tris-glycin gels for IL-6, IL-17, IL-23 and actin. The separated proteins were electrophoretically transferred onto the nitrocellulose membrane (Bio-Rad). Nonspecific binding was blocked with 0.5% tween20 in TBS (TBS-T) contain 5% nonfat milk for 1h at room temperature. The membranes were then incubated overnight at 4°C with individual primary antibodies then incubated with the HRP conjugated secondary antibodies at 1:10000 dilution in TBS-T. The protein bands were visualized with the enhanced chemiluminescence westernblotting detection system.

RNA isolation and real-time Q-PCR

RNA was isolated from spleen tissue using Trizol reagent (Invitrogen, Carlsbad, CA) and then precipitated with isopropanol and dissolved in RNA storage buffer (Ambion, Austin, TX). First strand cDNA was synthesized by ReverTra Ace qPCR RT Master Mix with gDNA Remover kit (Toyobo, Osaka, Japan) following manufacturers’ instruction. Specific primers for each gene were designed using primer3 software. Q-PCR was performed with primers as shown in Table 1.

Amplification of 1ul of cDNA was performed by SYBR mixture using iQTMSupermix PCR Master Mix (Bio-Rad Laboratories, Hercules, CA, USA). The PCR program used an initial step of 95°C for 3 min for pre-denaturation, followed by denaturation at 95°C, annealing and extension at 58°C using the CFX connector (Bio-Rad Laboratories, Hercules, CA, USA). Quantization of relative gene expression was calculated by the comparative Ct method (2−ΔΔCt) as described by the manufacturer. Data were normalized to GAPDH mRNA levels. Three independent experiments were carried out to study mRNA levels.

Splenocyte CD4+ T cells isolation and culture

The removed spleen was immediately transfered to 50ml tube containing PBS. For the cell isolation, the spleen was ground using a cell strainer (100 μm, nylon) and lymphocytes were separated using a Ficoll-Hypaque gradient. Splenic CD4+ T cells were isolated using the CD4+ T cells isolation kit from Miltenyi Biotec (Miltenyi Biotec) and cultured in RPMI1640 media. For differentiation to Treg cells, splenic CD4+ T cells were activated with anti-CD3 (0.5μg/ml) and CD28 (1μg/ml) antibodies and treated with anti TGF-β (5μg/ml) antibody for 3 days.

Flow cytometry analysis (FACS)

For Treg cell analysis, cells were permeabilized with fixation/permeabilzation buffer (eBioscience, San Diego, CA) and stained with Mouse Regulatory T cell Staining kit#2 (eBioscience, San Diego, CA) according to the manufacturer’s instruction. Briefly, after cell surface staining with anti-CD4-FITC and anti-CD25-PE for 30min, to block mouse Fc receptors, cell was incubated with CD16/CD32 for 15min. Then, followed by incubation with fixation/permeabilization buffer for 30 min and staining with anti-Foxp3-APC for 30min.

Histology and immunohistochemistry

On day 9, the mice were euthanized and the hind ankle joints were removed. Mouse joint tissues were fixed with 10% formalin, decalcified for 3 days in 10% EDTA and embedded in paraffin wax blocks. Five μm sections were stained with hematoxylin-eosin. For immune-histochemical staining, anti-IL-6 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), IL-17(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) andIL-23 (Abcam Ltd., Cambridge, UK) antibodies were used. To eliminate endogenous peroxidase activity, sections were treated with 3% H2O2 (Sigma, St. Louis, MO). Sections were subsequently treated with 10% normal serum (BD) and antibody labeling was detected using DakoREALTM EnVisionTM Detection systems, Peroxidase/DAB+, Rabbit/mouse (DAKO Corporation, Carpinteria, CA). The staining of joint tissue was determined semi-quantitatively using a four grade scale from 0 (little or no stain) to 4 (large number of positive cells).

Statistical analysis

All values in the results were expressed as mean ± SD. The significant differences between groups were determined using non-parametric statistic method, two tailed Mann-Whitney U test was used (PASW, Ver. 18.0. Chicago, IL). A value of p< 0.05 was considered statistically significant.

Results

Collagen antibody-induced arthritis was attenuated in the fat-1 mice

To determine whether n-3 PUFAs affected joint inflammation in collagen antibody-induced arthritis, male C57/B6 wild type (WT) mice and fat-1 transgenic mice were immunized with anti-collagen antibodies and monitored signs of arthritis until day 9. WT mice developed severe ankle swelling which was maximized on day 9. However, fat-1 transgenic mice showed significantly milder ankle swelling compared to WT mice (Fig 1A and 1B).

thumbnail
Fig 1. Clinical disease scores and ankle thickness in the WT and fat-1 mice in which arthritis was induced by anti-collagen antibodies.

Arthritis was induced with 4mg of collagen antibodies in the WT and fat-1 mice. Clinical arthritis scores (A) and ankle thickness (B) were monitored every other day until day 9. Values are the mean±SD (n = 5 mice/group). (*p<0.05, **p<0.01) WT: wild type. Statistical significance test was done by Mann-Whitney U-test.

https://doi.org/10.1371/journal.pone.0194331.g001

Clinical arthritis score was significantly lower in fat-1 mice than in WT at both day 7 (1.6±1.8, p = 0.012) and day 9 (1.5±1.6, p = 0.003). Ankle thickness was also significantly reduced in fat-1 mice compared to WT mice (1.82±0.11, p = 0.008) at day 9. Next, we conducted histologic evaluation in the joints of mice. The pathological assessment showed that histological score of joint tissue regarding inflammation, bone and cartilage damage decreased in fat-1 mice compared to WT (Fig 2).

thumbnail
Fig 2. N-3 PUFAs inhibits ankle joint inflammation and bone and cartilage damage in CAIA mice.

Ankle joints were collected on day 9, sectioned and stained with H&E in WT (A) and fat-1 mice (B). Photomicrographs (x40) are representative of at least three independent experiments. Further magnification of black-bordered box (x100) showed the typical inflammatory injuries in WT (C) and fat-1 mice (D). (E) Pathologic scores in the joint tissues of both groups were determined as described in the Materials and Methods. Values are the mean±SD (n = 5 mice/group).

https://doi.org/10.1371/journal.pone.0194331.g002

N-3 PUFAs inhibits the production of inflammatory cytokines in joint tissues

Infiltration of inflammatory cells into joint tissues causes chronic inflammation and bone destruction in RA. IL-17 plays a critical role in the development of chronic inflammation leading to joint damage in RA [20]. Therefore, the expression of inflammatory cytokines in joint tissues was investigated in the WT and fat-1 mice. In the sections of joint tissues from WT mice, a large number of synovial cells expressed IL-17, IL-6 and IL-23. However, fat-1 mice showed that lower number of synovial cells expressed these cytokines compared to the WT mice (Fig 3A). Next, we conducted western blots on the joint lysates. The protein expression levels of IL-17 were significantly lower in fat-1 mice compared to WT mice (p = 0.029) (Fig 3B).

thumbnail
Fig 3. Pro-inflammatory cytokine production in the joint, spleen and serum of fat-1 and WT mice.

Histological features of joint tissue were evaluated in the WT and fat-1 mice. Immunohistochemical staining (A) of cytokines was conducted in joint sections from WT and fat-1 mice. Ankle joints were collected on day 9, sectioned and stained with anti-IL-6, IL-23 and IL-17 antibodies. Western blots were conducted in the joint lysates from the WT and fat-1 mice (B). The joint lysates were collected on day 9 and blotted with anti-IL-6, IL-23 and IL-17 antibodies. The spleens were collected from WT and fat-1 mice on day 0 and 9. The expression of various pro-inflammatory cytokine in the spleen were measured by real-time Q-PCR (C). The serum were collected from WT and fat-1 mice on day 9. The expression of various pro-inflammatory cytokine were measured by ELISA (D). The results of three independent experiments with 5 mice/group are expressed as mean±SD. (*p<0.05, **p<0.01) Statistical significance test was done by Mann-Whitney U-test. WT: wild type, IL-7: interleukin 17, IL-6: interleukin 6, IL-23: interleukin 23.

https://doi.org/10.1371/journal.pone.0194331.g003

The splenic expansion of inflammatory cytokines is attenuated in fat-1 mice

RA is a systemic autoimmune disease, and the spleen contains a variety of immune cells producing pro-inflammatory cytokines which play important roles in the development of chronic arthritis. Therefore, we investigated the expression level of various pro-inflammatory cytokines in the spleen of both groups. First, the mRNA of IL-17 was highly expressed in the spleen of WT mice. In contrast, the levels of IL-17 mRNA expression significantly decreased in the spleen of fat-1 mice (p = 0.032). In addition, the mRNA expression levels of IL-6 and IL-23 which are involved in the generation of IL-17 were significantly lower in the fat-1 mice than in WT (IL-6; p = 0.016, IL-23; p = 0.016). However, the expression level of TNF-α was comparable between the WT and fat-1 mice (Fig 3C). Next, we investigated those cytokines in the serum of both groups. Only IL-6 was expressed in the serum of the WT mice, and the level of which was lower in the fat-1 mice, but there was no significant difference between the WT and fat-1 mice (p = 0.190) (Fig 3D).

The mRNA expression of Foxp3 in the spleen is elevated in the fat-1 mice

We obtained the spleen on day 9, and analyzed the proportion of Treg cells. The number of CD4+Foxp3+Treg cells in the spleen was determined using flow cytometry. The number of CD4+Foxp3+Treg cells tended to be higher in the fat-1 mice compared to WT mice (Fig 4A and 4B). But there was no significant difference (p = 0.264). Next, the mRNA expression of Foxp3 was measured by real-time Q-PCR. The mRNA expression level of Foxp3 is significantly higher in the spleen of fat-1 mice compared to WT mice (p = 0.009) (Fig 4E).

thumbnail
Fig 4. N-3 PUFAs induce the differentiation of CD4 T cells into splenic CD4+Foxp3+ regulatory T cells.

The splenocytes of the WT and fat-1 mice were isolated, stained, and sorted by flow cytometry using anti-CD4 and FoxP3 antibodies (A and B). The percentage of double positive on the CD4 and Foxp3 in the WT and fat-1 are shown in A and B. The mRNA expressions of Foxp3 were measured by real-time Q-PCR (E).Treg differentiation was higher in fat-1 splneocytes than in the WT mice (C and D). CD4+ T cells were cultured with anti-TGF-β antibody for Treg differentiation. Values are the mean±SD (n = 5 mice/group). Statistical significance test was done by Mann-Whitney U-test. WT: wild type.

https://doi.org/10.1371/journal.pone.0194331.g004

The differentiation of CD4+ T cells into CD4+CD25+Foxp3+ Treg cells in the fat-1 and WT mice

Treg cells have been studied as controllers of immune response to prevent the development of chronic inflammatory diseases. Therefore, we analyzed whether administration of n-3 PUFA induced the generation of Treg cells. WT and fat-1 mice were sacrificed without the induction of CAIA. The splenocytes from each group were stimulated with anti CD3, CD28 and TGF-β antibodies to see if there were any differences in the development of Treg cells. The number of CD4+Foxp3+Treg cells in fat-1 splenocytes was significantly higher than that in WT splenocytes (p = 0.038). Therefore, n-3 PUFA affected the development of CD4+Foxp3+Treg cells in the spleen (Fig 4C and 4D).

Discussion

The inflammatory cytokines expressed highly in RA joint enhance infiltration of inflammatory cells into RA joints culminating in joint tissue damage and bone destruction [21]. There are many reports that n-3 PUFAs improve inflammatory diseases such as panceratitis [16], diabetes [22] and asthma [17] by increase of anti-inflammatory effects. N-3 PUFAs are primarily obtained from diet. The dietary intake of fish oil has been considered beneficial in RA patient. Kromann N et al. reported intake of large amounts of fish oil decreased incidence of RA in Eskimos [23]. In animal study conducted in collagen-induced arthritis (CIA) model, prophylactic treatment with DHA significantly reduced arthritis severity and joint damage [24]. In a clinical trial, RA patients treated with n-3 PUFA showed reduced treatment failure and increased achievement of disease improvement [25]. In addition, it has been shown that n-3 PUFAs down-regulate pro-inflammatory cytokines and up-regulated anti-inflammatory mediators in RA [17, 26]. However, other studies reported controversial results [27, 28]. Therefore, the efficacy of n-3 PUFA on RA has not been clarified yet.

In this study, we verified whether n-3 PUFAs attenuated chronic autoimmune arthritis by using fat-1 mice which contain the fat-1 gene from Caenorhabditis elegans and synthesize n-3 PUFAs through converting n-6 into n-3 PUFA. The advantage of using fat-1 mice is to eliminate confounding factors of diet leading to providing reliable evidence. The representative animal model for the study of RA is the CIA mice. However, CIA is induced in mice with DBA/1 background rather than in those with a C57Bl/6 genetic background including the fat-1 mice. Therefore, we used the collagen antibody-induced arthritis model to induce arthritis in the fat-1 mice.

In our study, clinical phenotypes were generally improved in the fat-1 mice in which n-3 PUFAs decreased inflammation in the CAIA model. To find out the mechanisms by which n-3 PUFAs reduce inflammation in the joint tissues, we investigated cytokine profile. CD4 T cells are major population in synovial tissues and IL-17 has been shown in high level in synovial fluid of RA patients [29]. Since Th17 cells produce pro-inflammatory cytokine IL-17, Th17 cells have been suggested to play a critical role in the pathogenesis of RA. Th17 cells are differentiated from naïve CD4+ T cells. IL-6 and TGF-β promote Th17 differentiation, and IL-23 preserves the Th17 cell functional phenotypes [2]. On the other hand, Treg cells suppressed inflammatory signals by secretion of anti-inflammatory cytokines, such as TGF-β and IL-10 [30]. Treg cells are developed in either the thymus or lymphoid tissues such as spleen, lymph node and intestinal mucosa. Treg cells require CD28 co-stimulation during positive selection in the thymus in the presence of TGF-β, IL-2, and IL-15 [31]. In patient with RA, Treg cells are functionally defective, and restoring Treg cells function is important for the control of inflammation and restoring tolerance in RA patients [32].

Recently, N-3 PUFAs have been reported to increase the number of CD4+CD25+Foxp3+Treg cells[11, 3336] and to decrease Th17 cell differentiation and IL-17 production in other disease models including encephalomyelitis and psoriasis [3638]. In our study, n-3 PUFAs significantly decreased IL-6, IL-23 and IL-17 expression while increased the number of Treg cells in the joint tissues of the fat-1 mice. The spleen plays an important role in regulating the immune system and contains a variety of immune cells. The expression of IL-6, IL-23 and IL-17 was decreased while the expression of foxp3 was increased in the spleen of the fat-1 mice. The number of Treg cells was similar between the fat-1 and WT mice, but after stimulation, the differentiation to Treg cells was significantly higher in the fat-1 mice than in the WT. Therefore, our results suggest that anti-inflammatory function of n-3 PUFAs does not restrict to joint tissue but also works in the immune organs. However, in the serum, we could find only IL-6 and the level of which was not significantly different between the fat-1 and WT mice. This may account for the development of milder arthritis in C57Bl/6 strain induced by anti-collagen antibodies than in DBA/1 strain of the CIA model.

Previous studies have reported that the imbalance of Th17/Treg cells in the peripheral blood, may play an important role in RA development [3941]. Therefore, our results suggest that n-3 PUFAs could improve arthritis through restoring Th17/Treg cell balance (Fig 5). The restoring Th17/Treg cell balance could be a therapeutic strategies in RA patient such as type II collagen induces peripheral tolerance through the generation of Treg cell [4243].

thumbnail
Fig 5. Hypothetical mechanism by which n-3 PUFAs reduce the severity of arthritis in RA model.

Imbalance of Th17/Treg cells in the CAIA model could be restored by n-3 PUFA.

https://doi.org/10.1371/journal.pone.0194331.g005

Similarly n-3 PUFA, granulocyte macrophage colony-stimulation factor (GM-CSF) has been shown to prevent or attenuate autoimmunity in a number of mouse models of autoimmune disease by expanding regulatory T cells [4445]. Rowin J et al. reported that treatment with GM-CSF was associated with clinical improvement, an expansion of the circulating number of Foxp3+ cells [46]. The pro-inflammatory and regulatory effects of GM-CSF appear to depend on the dose and the presence of other relevant cytokines in the context of an immune response [47]. In contrast, a human monoclonal antibody against GM-CSF has been shown to have moderately positive benefits in patients with RA [48]. Based on these previous researches, GM-CSF might be has a synergic effect with n-3 PUFA and further study is needed. The result of in this study points to n-3 PUFA as potential therapeutic agents that contribute to improving the mechanisms that caused RA.

Some previous study reported that the affection of n-3 PUFA to M1 macrophage. In general, M1 macrophages are efficient producers of proinflammatory cytokines. Adipose tissue macrophage (ATM) is an anti-inflammatory phenotype and capable of excessive proinflammatory mediator production. Incorporation of n-3 PUFA in diet prevents mcrophage infilteration induced by high fat diet, which is similar with another research revealing reduction in ATM, along with transformation from M1 to M2 polarization stage [49].

On the side of osteoclastogenesis, dietary fish oil suppressed osteoclastogenesis by inhibiting the expression of M-CSF and RANK in the early stage of osteoclastogenesis [50], which is consistent with another research that DHA were the effective in inhibiting RANKL-induced osteoclast formation with the latter providing the strong inhibitory effects [51].

The anti-inflammatory effects of n-3PUFAs occur through multiple mechanisms. N-3PUFAs down regulated pro-inflammatory cytokine synthesis such as TNF-α, IL-1β, IL-6, IL-23 and IL-8 through decreased activation of nuclear transcription factors such as NF-kB [36, 37].

Our study had several limitations. First, we used collagen antibody-induced arthritis model which does not perfectly reflect the pathogenesis of human RA. Secondly, absence of severe inflammation in serum makes it difficult to find strong evidence of systemic immune response in C57Bl/6 strain. However, our CAIA model showed similar results with those found in the CIA model which depends on adaptive immune response.

In conclusion, we confirmed that n-3 PUFAs attenuated development of arthritis probably through inhibition of generation of IL-17 mediated by IL-6 and IL-23, and increased the expression of foxp3 in the fat-1 mice. These findings suggest that n-3 PUFAs might be a promising therapeutic agent for the treatment of RA.

Supporting information

S1 Data. The morphology scoring result of fat-1 and wild mice.

https://doi.org/10.1371/journal.pone.0194331.s002

(XLSX)

S2 Data. The pathology reading result of fat-1 and wild mice in day 9.

https://doi.org/10.1371/journal.pone.0194331.s003

(XLSX)

S3 Data. The RT-PCR result of inflammatory cytokines.

https://doi.org/10.1371/journal.pone.0194331.s004

(XLSX)

Acknowledgments

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (MEST) under Grant <grant number: NRF-2013R1A1A2057950>.

References

  1. 1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009; 21(373): 659–672.
  2. 2. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development cytokine profile and function of human interleukin 17 producing helper T cells. Nat Immunol. 2007; 8(9): 950–957. pmid:17676044
  3. 3. Chen Z, Tato CM, Muul L, Laurence A, O’Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56(9):2936–2946. pmid:17763419
  4. 4. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4): 345–350. pmid:17375096
  5. 5. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis. 2007; 66(3): 87–90.
  6. 6. Zhang P, Kim W, Zhou L, Wang N, Ly LH, McMurray DN, et al. Dietary fish oil inhibits antigen-specific murine Th1 cell development by suppression of clonal expansion. J Nutr. 2006; 136(9): 2391–2398. pmid:16920860
  7. 7. Monk JM, Hou TY, Turk HF, Weeks B, Wu C, McMurray DN, et al. Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. PLoS One. 2012;7(11): e49739 pmid:23166761
  8. 8. Monk JM, Jia Q, Callaway E, Weeks B, Alaniz RC, McMurray DN, et al. Th17 cell accumulation is decreased during chronic experimental colitis by (n-3) PUFA in Fat-1 mice. J Nutr. 2012; 142(1): 117–124. pmid:22131549
  9. 9. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab. 2007; 32(4): 619–634. pmid:17622276
  10. 10. Ferrucci L, Cherubini A, Bandinelli S, Bartail B, Corsi A, Lauretani F et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006;91: 439–446. pmid:16234304
  11. 11. Zhang P, Kim W, Zhou L, Wang N, Ly LH, McMurray DN, et al. Dietary fish oil inhibits antigen-specific murine Th1 cell development by suppression of clonal expansion. J Nutr. 2006;136: 2391–2398. pmid:16920860
  12. 12. Yessoufou A, Plé A, Moutairou K, Hichami A, Khan NA. Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells. J Lipid Res. 2009; 50(12): 2377–2388. pmid:19561360
  13. 13. Kang JX. Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids. 2007;77:263–267. pmid:18042365
  14. 14. Huang MJ, Wang L, Jin DD, Zhang ZM, Chen TY, Jia CH, et al. Enhancement of the synthesis of n-3 PUFAs in fat-1 transgenic mice inhibits mTORC1 signalling and delays surgically induced osteoarthritis in comparison with wild-type mice. Ann Rheum Dis.2014; 73(9): 1719–1727. pmid:23852692
  15. 15. Woo SJ, Lim K, Park SY, Jung MY, Lim HS, Jeon MG, et al. Endogenous conversion of n-6 to n-3 polyunsaturated fatty acids attenuates K/BxN serum-transfer arthritis in fat-1 mice. J Nutr Biochem. 2015;26(7): 713–720. pmid:25910895
  16. 16. Weylandt KH, Nadolny A, Kahlke L, Köhnke T, Schmöcker C, Wang J, et al. Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis. Biochim Biophys Acta. 2008;1782(11): 634–641. pmid:18832028
  17. 17. Jang HY, Lim K, Lee SM, Park BH. Effects of n-3 PUFA on the CD4⁺ type 2 helper T-cell-mediated immune responses in Fat-1 mice. Mol Nutr Food Res. 2014;58(2): 365–375 pmid:24019303
  18. 18. Hirose J, Tanaka S. Animal models for bone and joint disease. CIA, CAIA model. Clin Calcium. 2011;21(2): 253–259. pmid:21289422
  19. 19. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature. 2004;5: 427.
  20. 20. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol. 2008;53: 515–519.
  21. 21. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulateds tissue inflammation by productin interleukin 17. Nat Immunol. 2005; 6: 1133–1141 pmid:16200068
  22. 22. White PJ, Arita M, Taguchi R, Kang JX, Marette A. Transgenic restoration of long chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes. 2010;59: 3066–3073. pmid:20841610
  23. 23. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950–1974. Acta Med Scand. 1980;208(5): 401–406. pmid:7457208
  24. 24. Olson MV, Liu YC, Dangi B, Paul Zimmer J, Salem N Jr, Nauroth JM. Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis. Inflamm Res. 2013;62(12):1003–1013. pmid:24008816
  25. 25. Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2015;74(1): 89–95. pmid:24081439
  26. 26. Di Giuseppe D, Wallin A, Bottai M, Askling J, Wolk A. Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women. Ann Rheum Dis. 2014;73(11): 1949–1953. pmid:23940215
  27. 27. Park Y, Lee A, Shim SC, Lee JH, Choe JY, Ahn H, et al. Effect of n-3 polyunsaturated fatty acid supplementation in patients with rheumatoid arthritis: a 16-week randomized, double-blind, placebo-controlled, parallel-design multicenter study in Korea. J Nutr Biochem. 2013;24(7): 1367–1372. pmid:23333088
  28. 28. Wallace JM, McCabe AJ, Roche HM, Higgins S, Robson PJ, Gilmore WS, et al. The effect of low-dose fish oil supplementation on serum growth factors in healthy humans. Eur J Clin Nutr. 2000;54(9): 690–694. pmid:11002380
  29. 29. Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor B-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther. 2005;7: R139–R148. pmid:15642134
  30. 30. Baumgart M, Tompkins F, Leng J, Hesse M. Naturally occurring CD4+Foxp3+ regulatory T cells are an essential, IL-10-independent part of the immune regulatory network in Schistosomamansoni egg-induced inflammation. J Immunol. 2006;176(9): 5374–5387. pmid:16622005
  31. 31. Yuan X, Malek TR. Cellular and molecular determinants for the development of natural and induced regulatory T cells. Hum Immunol. 2012;73(8): 773–782. pmid:22659217
  32. 32. Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology. 2015;54(5): 768–775. pmid:25667434
  33. 33. Han SC, Kang GJ, Ko YJ, Kang HK, Moon SW, Ann YS, et al. Fermented fish oil suppresses T helper 1/2 cell response in a mouse model of atopic dermatitis via generation of CD4+CD25+Foxp3+ T cells. BMC Immunol. 2012;9(13): 44.
  34. 34. Iwami D, Zhang Q, Aramaki O, Nonomura K, Shirasugi N, Niimi M. Purified eicosapentaenoic acid induces prolonged survival of cardiac allografts and generates regulatory T cells. Am J Transplant. 2009;9(6): 1294–1307. pmid:19459813
  35. 35. Haitz KA, Anandasabapathy N. Docosahexaenoic Acid alleviates atopic dermatitis in mice by generating T regulatory cells and m2 macrophages. J Invest Dermatol. 2015;135(6): 1472–1474. pmid:25964266
  36. 36. Kong W, Yen JH, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation inhibis antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011;25(5):872–82. pmid:20854895
  37. 37. Qin S, Wen J, Bai XC, Chen TY, Zheng RC, Zhou GB, et al. Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Mol Med Rep. 2014;9(6): 2097–2104. pmid:24718773
  38. 38. Allen MJ, Fan YY, Monk JM, Hou TY, Barhoumi R, McMurray DN, et al. n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4⁺ T cells. J Nutr. 2014;144(8): 1306–1313. pmid:24944284
  39. 39. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum.2012;64(8): 2499–2503. pmid:22488116
  40. 40. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int. 2012;32(9): 2731–2736. pmid:21809006
  41. 41. Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int. 2012;32(4): 887–893. pmid:21221592
  42. 42. Farooq SM, Ashour HM. Type II collagen induces peripheral tolerance in BALB/c mice via the generation of CD8+ T regulatory cells. PLoS One. 2012;7(11):e48635 pmid:23133648
  43. 43. Faroog SM, Kumar A, Ashour HM. Eye-mediated immune tolerance to Type II collagen in arthritis-prone stains of mice. J cell Mol Med. 2014;18(12):2512–2518. pmid:25211510
  44. 44. Ganesh BB, Cheatem DM, Sheng JR, Vasu C, Prabhakar BS. GM-CSF-induced CD11c+CD8a- dendritic cells facilitate Foxp3+and IL-1 = +regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol. 2009;21:269–282. pmid:19174473
  45. 45. Sheng JR, Li L, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia. Clin Immunol. 2008;128:172–180. pmid:18502693
  46. 46. Rowin J, Thiruppathi M, arhebamen E, Sheng J, parabhakar BS, Meriggioli NM. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012; 46(3):449–453. pmid:22907239
  47. 47. Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H et al. Dual role of GM-CSF as a pro-inflammatory and regulatory cytokine: implication for immune therapy. J interferon cytokine Res. 2015;35(8);585–599. pmid:25803788
  48. 48. Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomized, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015; 74(6):1058–1064. pmid:24534756
  49. 49. Wang Y, Huang F. N-3 Polyunsaturated fatty acids and inflammation in obesity: local effect and systemic benefit. Biomed Res Int. 2015;581469. pmid:26339623
  50. 50. Makanishi A, Litsuka N, Tsukamoto I. Fishi oil suppressed bone resorption by inhibiting osteoclastogenesis through decreased expression of M-CSF, PU.1, MITF and RANK in ovariectomized rats. Mol Med Rep. 2013;7(6)1896–1903. pmid:23625116
  51. 51. Boeyens JC. Deepak V, Chua WH, Kruger MC, Joubert AM, Coetzee M. Effects of ω3-and ω-6-polyunsaturated fatty acids on RANKL-induced osteoclast differentiation of RAW264.7 cells: a comparative in vitro study. Nutrients. 2014;6(7);2584–2601. pmid:25010555